Oral Pre-exposure Prophylaxis (PrEP)NCT07221747
PathToScale: The PERSIST Trial
A study testing Enhanced continuation support package in people with Oral Pre-exposure Prophylaxis (PrEP) and Long-acting Injectable Cabotegravir for PrEP, run by Georgetown University at 1 site in Malawi.
Trial summary
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups. Read more about this study
- Who is it for?
- Ages 15 to 110 yearsHealthy volunteers can take part
- Conditions the study is for
- Oral Pre-exposure Prophylaxis (PrEP), Long-acting Injectable Cabotegravir for PrEP
- What is being tested?
- Enhanced continuation support package
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9,900 participants
- Where
- 1 siteMalawi
- Study dates
- 16 Feb 2026to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 110 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- •Inclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis will be applied per Ministry of Health guidelines. Per Ministry of Health guidelines, the following populations will be prioritized for long-acting injectable cabotegravir for pre-exposure prophylaxis distribution, following individual risk assessment:
- Individuals who are 15+ years old AND either
- Female sex workers (FSW) OR
- Men who have sex with men (MSM) OR
- Transgender individuals (TG) OR
- Women and adolescent girls and young women (AGYW) presenting at STI services and/or family planning and/or HIV testing services OR
- Breastfeeding women (BFW) OR
- Male partners of female sex workers and/or Men at high risk for HIV and/or men presenting with a syndromic or lab-confirmed sexually transmitted infections. All individuals initiated on long-acting injectable cabotegravir for pre-exposure prophylaxis 15 years or above will be included in the passively enrolled sample.
Who cannot join
- Per Ministry of Health guidelines, exclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis includes:
- Those living with HIV-1 or evidence of possible acute HIV infection OR Those with a prior Hepatitis B diagnosis OR Those with a known history of severe side effects to Cabotegravir Long Acting OR Those unwilling or unable to return for 3-monthly HIV testing or 2-monthly counseling and safety monitoring visits OR Clients currently on multi-drug resistance tuberculosis (MDR-TB) medications OR Clients currently taking post-exposure prophylaxis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Malawi1 site, 1 recruiting
- Recruiting
Community Health Science Unit
Lilongwe
Washington Ozituosauka
About this study
Official title: ACCELERATING THE PATH TO SCALE FOR INJECTABLE HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) in MALAWI: THE PERSIST TRIAL
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.
Read the detailed description
The study will test a package of implementation strategies to support continuation on pre-exposure prophylaxis (PrEP), with a particular focus on long-acting injectable cabotegravir (CAB LA). The study will prioritize impacts on PrEP continuation at 5-months and will secondarily consider alternate continuation endpoints, acceptability, feasibility, appropriateness and fidelity of implementation strategies among CAB LA users and providers. The study will use an efficient hybrid type 3 pragmatic cluster randomization. Clusters are defined as delivery sites, including primary health centers (PHCs) and private clinics serving the broader population and drop-in centers/community-based organizations providing CAB LA to prioritized populations including female sex workers, clients, men who have sex with men and transgender persons.
Clusters will be randomized to receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation vs. an enhanced bundle of clinical support and provider-focused implementation strategies to promote sustained PrEP use. Variable-constrained randomization will be applied to balance allocation by facility type (drop-in centre for female sex workers, drop-in centre for men who have sex with men, primary health clinic, hospital, private), and overall clinic/PrEP volume.
PrEP users will be passively enrolled into the cluster randomized trial and a subset actively enrolled for participation in the targeted research activities. De-identified programmatic data will be utilized from OCR technology called ScanForm, which was developed by QED PrEP to identify the number and demographic characteristics (gender, age, indication for PrEP) of oral and CAB LA PrEP users initiating PrEP modalities by site, switching from oral to CAB LA PrEP (and vice versa), and continuation rates.
Outcomes of PrEP persistence will be followed for at least 5 months. Follow-up will begin at the time of injectable or oral PrEP initiation. With a 6-month passive enrollment period across sites and at least 5 months of follow-up of all clients initiating oral or injectable PrEP, this will result in 5-11 months of follow-up data per facility.
In addition to the utilization of programmatic data documenting PrEP continuation overall, and by PrEP modality (oral vs. CAB LA), a number of discrete research activities will be undertaken to evaluate the secondary objectives of the cluster randomized trial. These include: (1) serial cross-sectional surveys with PrEP clients; (2) In-depth qualitative interviews with PrEP clients; (3) Fidelity assessments of implementation strategies.
During a quantitative analysis, the primary endpoint (continuation of CAB LA at 5 months) will be compared as an intention-to-treat analysis across clusters of clinics implementing the standard of care continuation support for CAB LA vs. clinics implementing the enhanced continuation support package. The primary analysis will be an unpaired t-test to compare cluster-level proportions between the two study arms for each of the primary endpoints. We will further apply log-binomial regression to evaluate the difference in the study arms adjusting for stratification variables and individual-level characteristics that may be associated with the outcome. Similar analytical approaches will be followed for secondary endpoints.
For qualitative analysis, clients across priority populations and delivery channels will be identified for in-depth interviews (IDIs). We will enroll 100 clients to complete an IDI. With a sample size of around n=100, we promote feasibility and representation. Notably as this is not an ethnographic study, we will not seek to reach saturation in any of the groups, but rather to ensure that a diverse set of perspectives and experiences are represented which will allow for greater understanding of consistencies and variations in CAB LA implementation across populations and delivery channels.
Across the IDIs, we will audio record transcripts and use rapid qualitative analysis methods to efficiently translate research findings. Rapid analysis will include the write-up of detailed notes within 24 hours of the interview by the note- taker, and generation of an analytic memo utilizing structured templates within 2-business days of the interview by the moderator, listening to the audio recording where necessary for clarification; the note taker and moderator will then jointly review the memo and reach consensus. Matrices will be completed for each interview and memos detailing emerging themes created, allowing for within and across participant comparisons. A thematic analysis utilizing the memos and field notes will be applied deductively using CFIR domains and valence rating, with inductive themes added; audio recordings will be transcribed for further cross-reference and quotes. This approach, common in implementation science, will allow for more rapid identification and application of findings.
- Being tested
- Standard of Care (SoC), Enhanced continuation support package
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard of Care (SoC)Behavioural
Participants will receive the standard of care per national guidelines of PrEP counseling, national program quality improvement activities, and follow up text messages and phone calls after missed visit.
Enhanced continuation support packageBehavioural
Participants will receive the SoC and bundle of enhanced PrEP continuation support strategies with the following provider, client and structural components:
- improving provider-client empathy and communication
- expert client/ peer 'Dolo wa PrEP'
- early openings of clinics
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care (SoC) | Active comparator | Receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation. Receives: Behavioral: Standard of Care (SoC) |
| Enhanced continuation support package | Active comparator | Enhanced bundle of clinical support and provider focused intervention package to promote sustained PrEP use. Receives: Behavioral: Standard of Care (SoC); Behavioral: Enhanced continuation support package |
What is being measured
The primary outcome is the main question the study is designed to answer.
PrEP continuation among CAB LA PrEP users of enhanced intervention verse SoC
PrEP continuation among CAB LA PrEP users at 5-months in the enhanced continuation support arm verse SoC continuation support arm without a product interruption that requires PrEP re-initiation
Measured: 5 months of follow-up after enrollment
Secondary outcomes (3)
PrEP continuation among oral PrEP users of enhanced intervention verse SoC
PrEP continuation among oral PrEP users at 5-months in the enhanced intervention verse SoC continuation support arms without product interruption requiring re-initiation
Measured: 5 months of follow-up after enrollment (window period 4-6 months based on client dosing schedule)
PrEP continuation among CAB LA PrEP users
PrEP continuation among CAB LA PrEP users at 3-months without product interruption requiring re-initiation
Measured: 3 months after enrollment
Assessment of PrEP use and intervention
Qualitative assessment of motivations for PrEP use, discontinuation and effectiveness of continuation support strategies
Measured: Up to 12 months after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2025
- Study start16 Feb 2026
- Primary completion31 Aug 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Pre-exposure Prophylaxis (PrEP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a parallel design with all intervention facilities implementing the enhanced continuation package of strategies or standard of care (SoC) simultaneously.
- Masking
- None (open label)
- Enrolment
- 9,900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Georgetown University
- Sponsor type
- University, hospital or other
- Collaborators
- Center for the Development of People, Centers for Disease Control and Prevention, Elizabeth Glaser Pediatric AIDS Foundation, Healthqual, Johns Hopkins Research Project, Malawi, Johns Hopkins Bloomberg School of Public Health, Blantyre District Health Office, Malawi, Lilongwe District Health Office, Malawi, Lighthouse Trust, Ministry of Health, Malawi, National AIDS Commission, Malawi, Pakachere Institute of Health and Development Communication, Partners in Hope, Inc., University of North Carolina, Chapel Hill, United States President's Emergency Plan for AIDS Relief, Washington University School of Medicine, Clinton Health Access Initiative Inc., Quantitative Engineering Design
- Responsible party
- Sponsor
- Investigators
- Charles Holmes, MD, MPH, Principal investigator, Georgetown University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07221747
- Sponsor's protocol ID
- STUDY00009615
- Status last verified
- Mar 2026
- First submitted
- 25 Oct 2025
- Last updated
- 4 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is not a plan to make IPD available. We are working with vulnerable populations and can make aggregate data available by request. Approval from principal investigators will be necessary to release de-identified data.
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ACCELERATING THE PATH TO SCALE FOR INJECTABLE HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) in MALAWI: THE PERSIST TRIAL
- ClinicalTrials.gov ID
- NCT07221747
- Acronym / sponsor ID
- STUDY00009615
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 9,900 participants (estimated)
- Lead sponsor
- Georgetown UniversityUniversity, hospital or other
- Collaborators
- Center for the Development of People, Centers for Disease Control and Prevention, Elizabeth Glaser Pediatric AIDS Foundation, Healthqual, Johns Hopkins Research Project, Malawi, Johns Hopkins Bloomberg School of Public Health, Blantyre District Health Office, Malawi, Lilongwe District Health Office, Malawi, Lighthouse Trust, Ministry of Health, Malawi, National AIDS Commission, Malawi, Pakachere Institute of Health and Development Communication, Partners in Hope, Inc., University of North Carolina, Chapel Hill, United States President's Emergency Plan for AIDS Relief, Washington University School of Medicine, Clinton Health Access Initiative Inc., Quantitative Engineering Design
- Study start
- 16 Feb 2026 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 28 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.
Detailed description
The study will test a package of implementation strategies to support continuation on pre-exposure prophylaxis (PrEP), with a particular focus on long-acting injectable cabotegravir (CAB LA). The study will prioritize impacts on PrEP continuation at 5-months and will secondarily consider alternate continuation endpoints, acceptability, feasibility, appropriateness and fidelity of implementation strategies among CAB LA users and providers. The study will use an efficient hybrid type 3 pragmatic cluster randomization. Clusters are defined as delivery sites, including primary health centers (PHCs) and private clinics serving the broader population and drop-in centers/community-based organizations providing CAB LA to prioritized populations including female sex workers, clients, men who have sex with men and transgender persons.
Clusters will be randomized to receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation vs. an enhanced bundle of clinical support and provider-focused implementation strategies to promote sustained PrEP use. Variable-constrained randomization will be applied to balance allocation by facility type (drop-in centre for female sex workers, drop-in centre for men who have sex with men, primary health clinic, hospital, private), and overall clinic/PrEP volume.
PrEP users will be passively enrolled into the cluster randomized trial and a subset actively enrolled for participation in the targeted research activities. De-identified programmatic data will be utilized from OCR technology called ScanForm, which was developed by QED PrEP to identify the number and demographic characteristics (gender, age, indication for PrEP) of oral and CAB LA PrEP users initiating PrEP modalities by site, switching from oral to CAB LA PrEP (and vice versa), and continuation rates.
Outcomes of PrEP persistence will be followed for at least 5 months. Follow-up will begin at the time of injectable or oral PrEP initiation. With a 6-month passive enrollment period across sites and at least 5 months of follow-up of all clients initiating oral or injectable PrEP, this will result in 5-11 months of follow-up data per facility.
In addition to the utilization of programmatic data documenting PrEP continuation overall, and by PrEP modality (oral vs. CAB LA), a number of discrete research activities will be undertaken to evaluate the secondary objectives of the cluster randomized trial. These include: (1) serial cross-sectional surveys with PrEP clients; (2) In-depth qualitative interviews with PrEP clients; (3) Fidelity assessments of implementation strategies.
During a quantitative analysis, the primary endpoint (continuation of CAB LA at 5 months) will be compared as an intention-to-treat analysis across clusters of clinics implementing the standard of care continuation support for CAB LA vs. clinics implementing the enhanced continuation support package. The primary analysis will be an unpaired t-test to compare cluster-level proportions between the two study arms for each of the primary endpoints. We will further apply log-binomial regression to evaluate the difference in the study arms adjusting for stratification variables and individual-level characteristics that may be associated with the outcome. Similar analytical approaches will be followed for secondary endpoints.
For qualitative analysis, clients across priority populations and delivery channels will be identified for in-depth interviews (IDIs). We will enroll 100 clients to complete an IDI. With a sample size of around n=100, we promote feasibility and representation. Notably as this is not an ethnographic study, we will not seek to reach saturation in any of the groups, but rather to ensure that a diverse set of perspectives and experiences are represented which will allow for greater understanding of consistencies and variations in CAB LA implementation across populations and delivery channels.
Across the IDIs, we will audio record transcripts and use rapid qualitative analysis methods to efficiently translate research findings. Rapid analysis will include the write-up of detailed notes within 24 hours of the interview by the note- taker, and generation of an analytic memo utilizing structured templates within 2-business days of the interview by the moderator, listening to the audio recording where necessary for clarification; the note taker and moderator will then jointly review the memo and reach consensus. Matrices will be completed for each interview and memos detailing emerging themes created, allowing for within and across participant comparisons. A thematic analysis utilizing the memos and field notes will be applied deductively using CFIR domains and valence rating, with inductive themes added; audio recordings will be transcribed for further cross-reference and quotes. This approach, common in implementation science, will allow for more rapid identification and application of findings.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a parallel design with all intervention facilities implementing the enhanced continuation package of strategies or standard of care (SoC) simultaneously.
| Arm | Type | Receives |
|---|---|---|
| Standard of Care (SoC) | Active comparator | Behavioral: Standard of Care (SoC)Receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation. |
| Enhanced continuation support package | Active comparator | Behavioral: Standard of Care (SoC), Behavioral: Enhanced continuation support packageEnhanced bundle of clinical support and provider focused intervention package to promote sustained PrEP use. |
Who may qualify
- Ages
- 15 to 110 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- •Inclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis will be applied per Ministry of Health guidelines. Per Ministry of Health guidelines, the following populations will be prioritized for long-acting injectable cabotegravir for pre-exposure prophylaxis distribution, following individual risk assessment:
- Individuals who are 15+ years old AND either
- Female sex workers (FSW) OR
- Men who have sex with men (MSM) OR
- Transgender individuals (TG) OR
Key exclusion criteria (2 listed)
- Per Ministry of Health guidelines, exclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis includes:
- Those living with HIV-1 or evidence of possible acute HIV infection OR Those with a prior Hepatitis B diagnosis OR Those with a known history of severe side effects to Cabotegravir Long Acting OR Those unwilling or unable to return for 3-monthly HIV testing or 2-monthly counseling and safety monitoring visits OR Clients currently on multi-drug resistance tuberculosis (MDR-TB) medications OR Clients currently taking post-exposure prophylaxis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard of Care (SoC)Participants will receive the standard of care per national guidelines of PrEP counseling, national program quality improvement activities, and follow up text messages and phone calls after missed visit. | Behavioural | Enhanced continuation support package, Standard of Care (SoC) |
| Enhanced continuation support packageParticipants will receive the SoC and bundle of enhanced PrEP continuation support strategies with the following provider, client and structural components: 1. improving provider-client empathy and communication 2. expert client/ peer 'Dolo wa PrEP' 3. early openings of clinics | Behavioural | Enhanced continuation support package |
Primary outcome
PrEP continuation among CAB LA PrEP users of enhanced intervention verse SoC
Time frame: 5 months of follow-up after enrollment
PrEP continuation among CAB LA PrEP users at 5-months in the enhanced continuation support arm verse SoC continuation support arm without a product interruption that requires PrEP re-initiation
3 secondary outcomes
PrEP continuation among oral PrEP users of enhanced intervention verse SoC
Time frame: 5 months of follow-up after enrollment (window period 4-6 months based on client dosing schedule)
PrEP continuation among CAB LA PrEP users
Time frame: 3 months after enrollment
Assessment of PrEP use and intervention
Time frame: Up to 12 months after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2026.
- Individual participant dataSharing planned: No. There is not a plan to make IPD available. We are working with vulnerable populations and can make aggregate data available by request. Approval from principal investigators will be necessary to release de-identified data.
Related trials for Oral Pre-exposure Prophylaxis (PrEP)
Recruiting
Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services
HIV, PrEP
Recruiting
BetterInfo on Women's PrEP Choices and Outcomes in Malawi
Long-acting Injectable Cabotegravir for PrEP, Oral Pre-Exposure Prophylaxis (PrEP)
Not yet recruitingPhase 2
Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR
Pregnancy, HIV Infections
RecruitingObservational study
PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.
HIV Infection, Sexual and Reproductive Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Charles Holmes, MD, MPH principal investigator
Georgetown University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Enhanced continuation support package in people with Oral Pre-exposure Prophylaxis (PrEP) and Long-acting Injectable Cabotegravir for PrEP, run by Georgetown University at 1 site in Malawi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malawi. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Charles Holmes, MD, MPH (+1 (202) 662-9000, charles.holmes@georgetown.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PrEP continuation among CAB LA PrEP users of enhanced intervention verse SoC (time frame: 5 months of follow-up after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2026.